Sudden indications of a regulatory thaw in the U.S. toward psychedelic medicine bode well for psychedelic stocks in 2022.

Numinus Wellness reports Q1 2022 results, including quarterly revenues of CAD$0.8 million and a gross profit of CAD$50,965.

Numinus announces all regulatory authorization and preparations have been completed for the next stage of MAPS’ clinical trial for MDMA-assisted psychotherapy.

Levitee Labs announces a CAD$3 million private placement with units priced at CAD$0.20 and a full warrant at CAD$0.40.

Awakn and MAPS to team up to address Alcohol Use Disorder in Europe.

Eleusis, a private psychedelics company, has announced it is going public via a merger with Silver Spike Acquisition Corp II.

Optimi Health submits a patent application for the extraction process for its natural psilocybin extract.

Mydecine signs an LOI to provide The Newly Institute with psilocybin and MDMA for use in Health Canada SAP-approved psychedelics-based therapy.

A new study conducted by The Harris Poll and Delic Holdings Corp found that 65% of affected Americans want access to psychedelics for mental health.

Novamind to host a Phase I clinical trial of a ketamine-assisted therapy for Opioid Use Disorder.